AU Patent

AU2007325918B2 — Transdermal delivery systems comprising bupivacaine

Assigned to Durect Corp · Expires 2013-10-17 · 13y expired

What this patent protects

Disclosed are bupivacaine transdermal delivery systems, and related methods.

USPTO Abstract

Disclosed are bupivacaine transdermal delivery systems, and related methods.

Drugs covered by this patent

donepezil-hydrochloride (DONEPEZIL HYDROCHLORIDE)

Patent Metadata

Patent number: AU2007325918B2
Jurisdiction: AU
Classification: —
Expires: 2013-10-17
Drug substance claim: No
Drug product claim: No
Assignee: Durect Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.